Yahoo Finance • 28 days ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, toda... Full story

Yahoo Finance • 2 months ago

NextCure GAAP EPS of -$11.29

* NextCure press release [https://seekingalpha.com/pr/20194108-nextcure-provides-business-update-and-reports-second-quarter-2025-financial-results] (NASDAQ:NXTC [https://seekingalpha.com/symbol/NXTC]): Q2 GAAP EPS of -$11.29. * Cash, c... Full story

Yahoo Finance • 2 months ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today... Full story

Yahoo Finance • 3 months ago

NextCure announces 1-for-12 reverse stock split effective July 14

NextCure, Inc. (NASDAQ:NXTC), currently trading at $0.45 with a market capitalization of $12.62 million, announced Thursday that its board of directors has approved a one-for-twelve reverse stock split of its common stock. The reverse stoc... Full story

Yahoo Finance • 4 months ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Init... Full story

Yahoo Finance • 4 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented... Full story

Yahoo Finance • 6 months ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, toda... Full story

Yahoo Finance • 7 months ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the sec... Full story

Yahoo Finance • 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-r... Full story

Yahoo Finance • 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modeling Update for ongoing Phase 1a clinical trial is ex... Full story

Yahoo Finance • 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year endCash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Next... Full story

Yahoo Finance • 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-r... Full story

Yahoo Finance • 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MAIn preclinical testing, NC181 demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and... Full story

Yahoo Finance • 2 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinica... Full story

Yahoo Finance • 2 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-... Full story

Yahoo Finance • 2 years ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Data Presented at the 2023 Military Health System Research Symposium show activity in animal model of acute spinal cord injury-induced immobilization BELTSVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a c... Full story

Yahoo Finance • 2 years ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-r... Full story

Yahoo Finance • 2 years ago

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with... Full story

Yahoo Finance • 2 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-re... Full story

Yahoo Finance • 2 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-... Full story